Multistage in silico approach to identify novel quinoline derivatives as potential c-kit kinase inhibitors

References

• Adam, R., et al. (2006). Hepatic resection for noncolorectal nonendocrine liver metastases: Analysis of 1452 patients and development of a prognostic model. Annals of Surgery, 244(4), 524–535.
   PubMed Web of Science ®Google Scholar
• Adenis, A., Blay, J.-Y., Bui-Nguyen, B., Bouché, O., Bertucci, F., Isambert, N., Bompas, E., Chaigneau, L., Domont, J., Ray-Coquard, I., Blésius, A., Van Tine, B. A., Bulusu, V. R., Dubreuil, P., Mansfield, C. D., Acin, Y., Moussy, A., Hermine, O., & Le Cesne, A. (2014). Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial. Annals of Oncology, 25(9), 1762–1769. https://doi.org/10.1093/annonc/mdu237
   PubMed Web of Science ®Google Scholar
• Adnan, M., Shamsi, A., Elasbali, A. M., Siddiqui, A. J., Patel, M., Alshammari, N., Alharethi, S. H., Alhassan, H. H., Bardakci, F., & Hassan, M. I. (2022). Structure-guided approach to discover tuberosin as a potent activator of pyruvate kinase M2, targeting cancer therapy. International Journal of Molecular Sciences, 23(21), 13172. https://doi.org/10.3390/ijms232113172
   PubMed Web of Science ®Google Scholar
• Anant, A., Ali, A., Ali, A., Gupta, G. D., & Asati, V. (2021). A Computational approach to discover potential quinazoline derivatives against CDK4/6 kinase. Journal of Molecular Structure, 1245, 131079. https://doi.org/10.1016/j.molstruc.2021.131079
   Web of Science ®Google Scholar
• Angiolini, M. (2020). The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success. Structural Biology in Drug Discovery: Methods, Techniques, and Practices, p. 363–393.
   Google Scholar
• Antonescu, C. R., Besmer, P., Guo, T., Arkun, K., Hom, G., Koryotowski, B., Leversha, M. A., Jeffrey, P. D., Desantis, D., Singer, S., Brennan, M. F., Maki, R. G., & DeMatteo, R. P. (2005). Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clinical Cancer Research, 11(11), 4182–4190. https://doi.org/10.1158/1078-0432.CCR-04-2245
   PubMed Web of Science ®Google Scholar
• Asati, V., Bharti, S. K., & Budhwani, A. K. (2017). 3D-QSAR and virtual screening studies of thiazolidine-2, 4-dione analogs: Validation of experimental inhibitory potencies towards PIM-1 kinase. Journal of Molecular Structure, 1133, 278–293. https://doi.org/10.1016/j.molstruc.2016.12.006
   Web of Science ®Google Scholar
• Asati, V., Mahapatra, D. K., & Bharti, S. K. (2014). Thiazolidine-2, 4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents. European Journal of Medicinal Chemistry, 87, 814–833. https://doi.org/10.1016/j.ejmech.2014.10.025
   PubMed Web of Science ®Google Scholar
• Asati, V., Thakur, S. S., Upmanyu, N., & Bharti, S. K. (2018). Virtual Screening, Molecular Docking, and DFT Studies of Some Thiazolidine‐2, 4‐diones as Potential PIM‐1 Kinase Inhibitors. ChemistrySelect, 3(1), 127–135. https://doi.org/10.1002/slct.201702392
   Web of Science ®Google Scholar
• Bajaj, S., Asati, V., Singh, J., & Roy, P. P. (2015). 1, 3, 4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents. European Journal of Medicinal Chemistry, 97, 124–141. https://doi.org/10.1016/j.ejmech.2015.04.051
   PubMed Web of Science ®Google Scholar
• Berry, S. J., Coffey, D. S., Walsh, P. C., & Ewing, L. L. (1984). The development of human benign prostatic hyperplasia with age. Journal of Urology, 132(3), 474–479. https://doi.org/10.1016/s0022-5347(17)49698-4
   PubMed Web of Science ®Google Scholar
• Bhattacharya, S., Asati, V., Ali, A., Ali, A., & Gupta, G. D. (2022). In-silico studies for the development of novel RET inhibitors for cancer treatment. Journal of Molecular Structure, 1251, 132040. https://doi.org/10.1016/j.molstruc.2021.132040
   Web of Science ®Google Scholar
• Bhattacharya, S., Asati, V., Mishra, M., Das, R., Kashaw, V., & Kashaw, S. K. (2021). Integrated computational approach on sodium-glucose co-transporter 2 (SGLT2) Inhibitors for the development of novel antidiabetic agents. Journal of Molecular Structure, 1227, 129511. https://doi.org/10.1016/j.molstruc.2020.129511
   Web of Science ®Google Scholar
• Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000). Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. Journal of Pharmacology and Experimental Therapeutics, 295(1), 139–145.
   PubMed Web of Science ®Google Scholar
• Burch, J., & Collins, B. (2021). Oxford handbook of gastrointestinal nursing. Oxford University Press.
   Google Scholar
• Chandel, S., Singh, R., Gautam, A., & Ravichandiran, V. (2022). Screening of Azadirachta indica phytoconstituents as GSK-3β inhibitor and its implication in neuroblastoma: Molecular docking, molecular dynamics, MM-PBSA binding energy, and in-vitro study. Journal of Biomolecular Structure & Dynamics, 40(23), 12827–12840. https://doi.org/10.1080/07391102.2021.1977705
   PubMed Web of Science ®Google Scholar
• Corless, C. L., Fletcher, J. A., & Heinrich, M. C. (2004). Biology of gastrointestinal stromal tumors. Journal of Clinical Oncology, 22(18), 3813–3825. https://doi.org/10.1200/JCO.2004.05.140
   PubMed Web of Science ®Google Scholar
• Costa, M. G. S., Batista, P. R., Bisch, P. M., & Perahia, D. (2015). Exploring free energy landscapes of large conformational changes: Molecular dynamics with excited normal modes. Journal of Chemical Theory and Computation, 11(6), 2755–2767. https://doi.org/10.1021/acs.jctc.5b00003
   PubMed Web of Science ®Google Scholar
• Cruz, S., Gomes, S. E., Borralho, P. M., Rodrigues, C. M. P., Gaudêncio, S. P., & Pereira, F. (2018). In silico HCT116 human colon cancer cell-based models en route to the discovery of lead-like anticancer drugs. Biomolecules, 8(3), 56. https://doi.org/10.3390/biom8030056
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter, M., Cools, J., Dumez, H., Sciot, R., Stul, M., Mentens, N., Vranckx, H., Wasag, B., Prenen, H., Roesel, J., Hagemeijer, A., Van Oosterom, A., & Marynen, P. (2005). Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology, 128(2), 270–279. https://doi.org/10.1053/j.gastro.2004.11.020
   PubMed Web of Science ®Google Scholar
• Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. M., & Joensuu, H. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine, 347(7), 472–480. https://doi.org/10.1056/NEJMoa020461
   PubMed Web of Science ®Google Scholar
• Dionne, U., Chartier, F. J. M., López de Los Santos, Y., Lavoie, N., Bernard, D. N., Banerjee, S. L., Otis, F., Jacquet, K., Tremblay, M. G., Jain, M., Bourassa, S., Gish, G. D., Gagné, J.-P., Poirier, G. G., Laprise, P., Voyer, N., Landry, C. R., Doucet, N., & Bisson, N. (2018). Direct phosphorylation of SRC homology 3 domains by tyrosine kinase receptors disassembles ligand-induced signaling networks. Molecular Cell, 70(6), 995–1007. e11. https://doi.org/10.1016/j.molcel.2018.05.013
   PubMed Web of Science ®Google Scholar
• Singh, R., Gautam, A., Chandel, S., Sharma, V., Ghosh, A., Dey, D., Roy, S., Ravichandiran, V., & Ghosh, D. (2021). Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.In Silico Pharmacology, 9(1), 27. https://doi.org/10.1007/s40203-021-00089-8
   Google Scholar
• Giamas, G., Man, Y. L., Hirner, H., Bischof, J., Kramer, K., Khan, K., Ahmed, S. S. L., Stebbing, J., & Knippschild, U. (2010). Kinases as targets in the treatment of solid tumors. Cellular Signalling, 22(7), 984–1002. https://doi.org/10.1016/j.cellsig.2010.01.011
   PubMed Web of Science ®Google Scholar
• Gill, A. J. (2018). Succinate dehydrogenase (SDH)‐deficient neoplasia. Histopathology, 72(1), 106–116. https://doi.org/10.1111/his.13277
   PubMed Web of Science ®Google Scholar
• Gromova, P., Ralea, S., Lefort, A., Libert, F., Rubin, B. P., Erneux, C., & Vanderwinden, J.-M. (2009). Kit K641E oncogene up‐regulates Sprouty homolog 4 and trophoblast glycoprotein in interstitial cells of Cajal in a murine model of gastrointestinal stromal tumours. Journal of Cellular and Molecular Medicine, 13(8a), 1536–1548. https://doi.org/10.1111/j.1582-4934.2009.00768.x
   PubMed Web of Science ®Google Scholar
• Gulzar, M., Ali, S., Khan, F. I., Khan, P., Taneja, P., & Hassan, M. I. (2019). Binding mechanism of caffeic acid and simvastatin to the integrin linked kinase for therapeutic implications: A comparative docking and MD simulation studies. Journal of Biomolecular Structure & Dynamics, 37(16), 4327–4337. https://doi.org/10.1080/07391102.2018.1546621
   PubMed Web of Science ®Google Scholar
• Guo, T., Agaram, N. P., Wong, G. C., Hom, G., D'Adamo, D., Maki, R. G., Schwartz, G. K., Veach, D., Clarkson, B. D., Singer, S., DeMatteo, R. P., Besmer, P., & Antonescu, C. R. (2007). Sorafenib inhibits the imatinib-resistant KIT T670I gatekeeper mutation in gastrointestinal stromal tumor. Clinical Cancer Research, 13(16), 4874–4881. https://doi.org/10.1158/1078-0432.CCR-07-0484
   PubMed Web of Science ®Google Scholar
• Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000). Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, 96(3), 925–932. https://doi.org/10.1182/blood.V96.3.925.015k50_925_932
   PubMed Web of Science ®Google Scholar
• Irie, T., & Sawa, M. (2018). 7-Azaindole: A versatile scaffold for developing kinase inhibitors. Chemical & Pharmaceutical Bulletin, 66(1), 29–36. https://doi.org/10.1248/cpb.c17-00380
   PubMed Web of Science ®Google Scholar
• Joensuu, H., Fletcher, C., Dimitrijevic, S., Silberman, S., Roberts, P., & Demetri, G. (2002). Management of malignant gastrointestinal stromal tumours. The Lancet Oncology, 3(11), 655–664. https://doi.org/10.1016/s1470-2045(02)00899-9
   PubMed Web of Science ®Google Scholar
• Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S., Capdeville, R., Dimitrijevic, S., Druker, B., & Demetri, G. D. (2001). Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. New England Journal of Medicine, 344(14), 1052–1056. https://doi.org/10.1056/NEJM200104053441404
   PubMed Web of Science ®Google Scholar
• Khan, M. F., Verma, G., Akhtar, W., Shaquiquzzaman, M., Akhter, M., Rizvi, M. A., & Alam, M. M. (2019). Pharmacophore modeling, 3D-QSAR, docking study and ADME prediction of acyl 1, 3, 4-thiadiazole amides and sulfonamides as antitubulin agents. Arabian Journal of Chemistry, 12(8), 5000–5018. https://doi.org/10.1016/j.arabjc.2016.11.004
   Web of Science ®Google Scholar
• Knab, L. M., & Yang, A. (2016). Gastric and Small Bowel Tumors. Gastrointestinal Malignancies, p. 1–16.
   Google Scholar
• Kumari, R., Kumar, R., Open Source Drug Discovery, C., & Lynn, A, Open Source Drug Discovery Consortium. (2014). g_mmpbsa—A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. https://doi.org/10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Ma, Z., Zhou, J., Liu, K., Chen, S., Wu, Q., Peng, L., Zhao, W., & Zhu, S. (1997). A Phase III randomized study of interleukin‐2 lymphokine‐activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Radiation Oncology (London, England), 19(1), 8–49. https://doi.org/10.1002/(SICI)1097-0142(19970701)80:1<42::AID-CNCR6>3.0.CO;2-H
   Google Scholar
• Mahapatra, D. K., Bharti, S. K., & Asati, V. (2015). Anti-cancer chalcones: Structural and molecular target perspectives. European Journal of Medicinal Chemistry, 98, 69–114. https://doi.org/10.1016/j.ejmech.2015.05.004
   PubMed Web of Science ®Google Scholar
• Mahor, A., Sawant, D. M., & Goyal, A. K. (2023). The Custom R group Enumeration with various R group Libraries at designated Sites on Amphotericin B. Current Computer-Aided Drug Design, 19(5), 382–390. https://doi.org/10.2174/1573409919666230123144712
   PubMed Web of Science ®Google Scholar
• Mallick, C., Mishra, M., Asati, V., Kashaw, V., Das, R., Iyer, A. K., & Kashaw, S. K. (2022). Integrated Computational Analysis on Some Indolo-quinoline Derivatives for the Development of Novel Antiplasmodium Agents: CoMFA, Pharmacophore Mapping, Molecular Docking and ADMET Studies. Current Signal Transduction Therapy, 17(1), 12–58. https://doi.org/10.2174/1574362416666210906155929
   Google Scholar
• Miettinen, M., Sobin, L. H., & Sarlomo-Rikala, M. (2000). Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Modern Pathology, 13(10), 1134–1142. https://doi.org/10.1038/modpathol.3880210
   PubMed Web of Science ®Google Scholar
• Pal, S., Kumar, V., Kundu, B., Bhattacharya, D., Preethy, N., Reddy, M. P., & Talukdar, A. (2019). Ligand-based pharmacophore modeling, virtual screening and molecular docking studies for discovery of potential topoisomerase I inhibitors. Computational and Structural Biotechnology Journal, 17, 291–310. https://doi.org/10.1016/j.csbj.2019.02.006
   PubMed Web of Science ®Google Scholar
• Pawson, T. (2002). Regulation and targets of receptor tyrosine kinases. European Journal of Cancer (Oxford, England: 1990), 38 Suppl 5, S3–S10. https://doi.org/10.1016/s0959-8049(02)80597-4
   PubMed Web of Science ®Google Scholar
• Rathore, A., Asati, V., Mishra, M., Das, R., Kashaw, V., & Kashaw, S. K. (2022). Computational approaches for the design of novel dopamine D2 and serotonin 5-HT2A receptor dual antagonist towards schizophrenia. In Silico Pharmacology, 10(1), 7. https://doi.org/10.1007/s40203-022-00121-5
   PubMedGoogle Scholar
• Rondla, R., Padma Rao, L. S., Ramatenki, V., Vadija, R., Mukkera, T., Potlapally, S. R., & Vuruputuri, U. (2017). Azolium analogues as CDK4 inhibitors: Pharmacophore modeling, 3D QSAR study and new lead drug discovery. Journal of Molecular Structure, 1134, 482–491. https://doi.org/10.1016/j.molstruc.2016.12.106
   Web of Science ®Google Scholar
• Saha, M., Gupta, S., Dhiman, S., Asati, V., Ali, A., & Ali, A. (2023). Field and atom-based 3D-QSAR models of chromone (1-benzopyran-4-one) derivatives as MAO inhibitors. Journal of Biomolecular Structure & Dynamics, 41(21), 12171–12185. p https://doi.org/10.1080/07391102.2023.2166122
   PubMedGoogle Scholar
• Singh, R., Gautam, A., Chandel, S., Sharma, V., Ghosh, A., Dey, D., Roy, S., Ravichandiran, V., & Ghosh, D. (2021). Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post‐translational modification: A multiple target approach. In Silico Pharmacology, 9(1), 27. https://doi.org/10.1007/s40203-021-00089-8
   PubMedGoogle Scholar
• Thomas, R., Mary, Y. S., Resmi, K. S., Narayana, B., Sarojini, B. K., Vijayakumar, G., & Van Alsenoy, C. (2019). Two neoteric pyrazole compounds as potential anti-cancer agents: Synthesis, electronic structure, physico-chemical properties and docking analysis. Journal of Molecular Structure, 1181, 455–466. https://doi.org/10.1016/j.molstruc.2019.01.003
   Web of Science ®Google Scholar
• Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C. W., Van Glabbeke, M., Bertulli, R., & Judson, I. (2004). Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet (London, England), 364(9440), 1127–1134. https://doi.org/10.1016/S0140-6736(04)17098-0
   PubMed Web of Science ®Google Scholar
• Wang, J., Hou, T., & Xu, X. (2006). Recent advances in free energy calculations with a combination of molecular mechanics and continuum models. Current Computer Aided-Drug Design, 2(3), 287–306. https://doi.org/10.2174/157340906778226454
   Web of Science ®Google Scholar
• Wang, Y.-M., Gu, M.-L., & Ji, F. (2015). Succinate dehydrogenase-deficient gastrointestinal stromal tumors. World Journal of Gastroenterology, 21(8), 2303–2314. https://doi.org/10.3748/wjg.v21.i8.2303
   PubMed Web of Science ®Google Scholar
• Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A. L., Mestan, J., Daley, G. Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright, R. D., Gilliland, D. G., & Griffin, J. D. (2005). Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7(2), 129–141. https://doi.org/10.1016/j.ccr.2005.01.007
   PubMed Web of Science ®Google Scholar
• Wu, C.-E., Tzen, C.-Y., Wang, S.-Y., & Yeh, C.-N. (2019). Clinical diagnosis of gastrointestinal stromal tumor (GIST): from the molecular genetic point of view. Cancers, 11(5), 679. https://doi.org/10.3390/cancers11050679
   PubMed Web of Science ®Google Scholar
• Yamamoto, H., & Oda, Y. (2015). Gastrointestinal stromal tumor: Recent advances in pathology and genetics. Pathology International, 65(1), 9–18. https://doi.org/10.1111/pin.12230
   PubMed Web of Science ®Google Scholar
• Zuccotto, F., Ardini, E., Casale, E., & Angiolini, M. (2010). Through the “gatekeeper door”: exploiting the active kinase conformation. Journal of Medicinal Chemistry, 53(7), 2681–2694. https://doi.org/10.1021/jm901443h
   PubMed Web of Science ®Google Scholar